NuVasive Inc. (NSDQ:NUVA) said the FDA granted pre-market approval for its PCM cervical disc implant, sending NUVA shares up more than 2% on Wall Street today.
The San Diego-based medical device company said the implant is designed to preserve motion in the cervical spine, in lieu of a standard fusion procedure. The FDA nod came after a 403-patient investigation device exemption trial, according to NuVasive.